OraSure Technologies, Inc. (NASDAQ:OSUR) Short Interest Down 20.4% in September – MarketBeat
Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
OraSure Technologies, Inc. (NASDAQ:OSUR – Get Rating) saw a significant drop in short interest in September. As of September 30th, there was short interest totalling 2,340,000 shares, a drop of 20.4% from the September 15th total of 2,940,000 shares. Based on an average daily trading volume, of 935,100 shares, the short-interest ratio is presently 2.5 days. Approximately 3.4% of the shares of the stock are short sold.
Analyst Ratings Changes
Separately, StockNews.com began coverage on OraSure Technologies in a research note on Wednesday. They set a “sell” rating on the stock.
Insider Buying and Selling
In other news, Director Michael Celano purchased 12,000 shares of the stock in a transaction on Friday, August 12th. The shares were acquired at an average price of $4.49 per share, for a total transaction of $53,880.00. Following the completion of the transaction, the director now directly owns 111,823 shares of the company’s stock, valued at approximately $502,085.27. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. In other news, Director Ronny B. Lancaster purchased 50,000 shares of the stock in a transaction on Friday, August 26th. The shares were acquired at an average price of $4.00 per share, for a total transaction of $200,000.00. Following the completion of the transaction, the director now directly owns 104,782 shares of the company’s stock, valued at approximately $419,128. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Michael Celano purchased 12,000 shares of the stock in a transaction on Friday, August 12th. The shares were purchased at an average price of $4.49 per share, for a total transaction of $53,880.00. Following the transaction, the director now directly owns 111,823 shares of the company’s stock, valued at $502,085.27. The disclosure for this purchase can be found here. Over the last quarter, insiders have acquired 64,200 shares of company stock worth $263,538. Corporate insiders own 2.20% of the company’s stock.
Hedge Funds Weigh In On OraSure Technologies
Several large investors have recently made changes to their positions in OSUR. FMR LLC raised its holdings in OraSure Technologies by 249.6% in the 2nd quarter. FMR LLC now owns 10,687 shares of the medical instruments supplier’s stock worth $29,000 after acquiring an additional 7,630 shares during the last quarter. 1832 Asset Management L.P. purchased a new position in OraSure Technologies in the 1st quarter worth approximately $40,000. Ronald Blue Trust Inc. purchased a new position in OraSure Technologies in the 2nd quarter worth approximately $49,000. Canandaigua National Corp purchased a new position in OraSure Technologies in the 3rd quarter worth approximately $49,000. Finally, Legacy Advisors LLC raised its holdings in OraSure Technologies by 68.6% in the 2nd quarter. Legacy Advisors LLC now owns 20,650 shares of the medical instruments supplier’s stock worth $56,000 after acquiring an additional 8,403 shares during the last quarter. 90.20% of the stock is currently owned by hedge funds and other institutional investors.
OraSure Technologies Stock Up 2.4 %
Shares of NASDAQ OSUR traded up $0.09 during trading hours on Friday, hitting $3.88. The company’s stock had a trading volume of 484,065 shares, compared to its average volume of 810,320. OraSure Technologies has a 12 month low of $2.62 and a 12 month high of $11.45. The business has a 50-day simple moving average of $3.99 and a 200-day simple moving average of $4.31.
OraSure Technologies (NASDAQ:OSUR – Get Rating) last posted its earnings results on Tuesday, August 9th. The medical instruments supplier reported ($0.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.14. OraSure Technologies had a negative return on equity of 12.92% and a negative net margin of 24.18%. The company had revenue of $80.23 million for the quarter, compared to analysts’ expectations of $69.91 million. During the same period last year, the firm earned ($0.02) earnings per share. OraSure Technologies’s quarterly revenue was up 39.3% on a year-over-year basis. Sell-side analysts forecast that OraSure Technologies will post -0.67 earnings per share for the current year.
About OraSure Technologies
(Get Rating)
OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, Diagnostics and Molecular Solutions. The company's principal products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.
Further Reading
- Get a free copy of the StockNews.com research report on OraSure Technologies (OSUR)
- MarketBeat: Week in Review 10/10-10/14
- Is Taiwan Semiconductor A Good Investment For 2023?
- Trinseo Gets A Downgrade But That Doesn’t Stop It From Advancing
- Delta Air Lines Looks Ready To Take Off
- Does the Zillow Stock Forecast Hint Toward a Turnaround?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider OraSure Technologies, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and OraSure Technologies wasn’t on the list.
While OraSure Technologies currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Complete the form below to receive the latest headlines and analysts’ recommendations for your stocks with our free daily email newsletter:
Brian Mulberry brings three large-cap ideas today and discusses why one utility may have potential beyond the traditional role of a dividend payer
Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat’s trending stocks report.
Identify stocks that meet your criteria using seven unique stock screeners. See what’s happening in the market right now with MarketBeat’s real-time news feed. Export data to Excel for your own analysis.
MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.
Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.
Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.
As Featured By:
MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.
Twitter Facebook StockTwits Financial Juice YouTube
© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.
Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds
© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer.